Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis<sup>△</sup>

Xuan Zhou; Xue-feng Yang

Your Location：

Home >

Browse articles >

Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis^△

中国医学科学杂志（英文版） 2014年第4期页码：231-235

• 论著 • | Updated：2024-04-10

- Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis^△
- Affiliations：
  
  Department of Gastroenterology, Affiliated Nanhua Hospital, University of South China,Hunan,Hengyang,China,421002
- Author bio：
- Funds：
- DOI：
  中图分类号：
- 网络出版日期：2014-11-28，
  
  纸质出版日期：2014
- Accepted：
Scan QR Code
Xuan Zhou, Xue-feng Yang. Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis^△[J]. 中国医学科学杂志（英文版）, 2014,(4):231-235.

Xuan Zhou, Xue-feng Yang. Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis[J]. Chinese medical sciences journal, 2014, (4): 231-235.
Xuan Zhou, Xue-feng Yang. Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis^△[J]. 中国医学科学杂志（英文版）, 2014,(4):231-235. DOI：

Xuan Zhou, Xue-feng Yang. Progress of Targeting Transforming Growth Factor-β1 Small Interfering RNA in Liver Fibrosis[J]. Chinese medical sciences journal, 2014, (4): 231-235. DOI：

摘要

Liver fibrosis is a common pathological consequence of a variety of chronic stimuli

including viral

autoimmune

drug-induced

cholestatic and metabolic diseases. Fibrosis is driven by a dynamic process involving increased synthesis of matrix components and a failure of physiological mechanisms of matrix turnover. Activation of hepatic stellate cells (HSCs) remains a central event in fibrosis. HSCs are the main source of extracellular matrix (ECM). Transforming growth factor-beta (TGF-β)

which is the fibrogenic master cytokine

can induce the activation of HSCs to produce a large amount of ECM

and is capable of inducing apoptosis of liver cells. RNA interference (RNAi) is a novel gene disruption technology. Studies have shown that small interfering RNA (siRNA) targeting TGF-β1 may inhibit the activation and proliferation of HSCs

suppress ECM synthesis and block liver fibrosis. TGF-β1 siRNA-mediated gene silencing therapy provides a new avenue for liver fibrosis. This review summarizes recent progresses in research on HSCs

TGF-β1 and TGF-β1 siRNA in liver fibrosis.

Abstract

Liver fibrosis is a common pathological consequence of a variety of chronic stimuli

including viral

autoimmune

drug-induced

which is the fibrogenic master cytokine

can induce the activation of HSCs to produce a large amount of ECM

suppress ECM synthesis and block liver fibrosis. TGF-β1 siRNA-mediated gene silencing therapy provides a new avenue for liver fibrosis. This review summarizes recent progresses in research on HSCs

TGF-β1 and TGF-β1 siRNA in liver fibrosis.

关键词

Keywords

references

浏览量

830

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

TRANSFORMING GROWTH FACTOR-β AND FIBROBLAST GROWTH FACTOR INDUCE LENS EPITHELIAL EXPLANT METAPLASIA:IMPLICATIONS FOR THE FORMATION OF SUBCAPSULAR OPACIFICATION

KNOCKDOWN OF SURVIVIN EXPRESSION BY SMALL INTERFERING RNA SUPPRESSES PROLIFERATION OF TWO HUMAN CANCER CELL LINES

Roles of the Lipid Metabolism in Hepatic Stellate Cells Activation^△

Relation Between Cellular Senescence and Liver Diseases